Chemotherapy continuity and incidence of febrile neutropenia with CHOP therapy in an outpatient setting

  • Authors:
    • Eiseki Usami
    • Michio Kimura
    • Mina Iwai
    • Shoya Takenaka
    • Hitomi Teramachi
    • Tomoaki Yoshimura
  • View Affiliations

  • Published online on: January 25, 2016     https://doi.org/10.3892/mco.2016.738
  • Pages: 591-596
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) regimen is considered to be a standard treatment for non‑Hodgkin's lymphoma (NHL). Patients receiving CHOP chemotherapy often experience febrile neutropenia (FN) due to myelotoxicity. The proper management of FN is essential to guarantee a positive outcome of the NHL treatment. Therefore, the present study retrospectively examined chemotherapy continuity and the incidence of FN during CHOP therapy in an outpatient setting. The subjects were 136 patients who received CHOP chemotherapy between January 2012 and December 2014. A total of 31 patients unable to be treated in an outpatient setting were excluded from the study. Of the remaining 105 patients, 73 patients who did not require hospitalization during the chemotherapy treatment were included in the non‑hospitalized group, and 32 patients who required hospitalization during chemotherapy treatment were included in the re‑hospitalization group. The numbers of patients from these two groups who completed the planned treatment were 71 and 24, respectively (P<0.01). In addition, the duration of granulocyte‑colony stimulating factor (G‑CSF) treatment was 5.3±1.22 and 6.1±1.46 days, respectively (P<0.01). The numbers of patients experiencing FN in an outpatient setting were 14 and 19, respectively (P<0.01). During administration of primary prophylaxis with G‑CSF, the incidence of FN was 21.0% (22/105) in cycle 1. In conclusion, the present study has revealed a requirement to educate patients about infection prevention prior to the first cycle of chemotherapy. Patients who require the administration of long‑ term G‑CSF are at risk of unplanned re‑hospitalization, and treating them with polyethylene glycol G‑CSF to reduce the number of required injections should be considered as an option. Therefore, proper supportive therapy and management of infection are important to safely treat patients with CHOP in an outpatient setting.
View Figures
View References

Related Articles

Journal Cover

April 2016
Volume 4 Issue 4

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Usami, E., Kimura, M., Iwai, M., Takenaka, S., Teramachi, H., & Yoshimura, T. (2016). Chemotherapy continuity and incidence of febrile neutropenia with CHOP therapy in an outpatient setting. Molecular and Clinical Oncology, 4, 591-596. https://doi.org/10.3892/mco.2016.738
MLA
Usami, E., Kimura, M., Iwai, M., Takenaka, S., Teramachi, H., Yoshimura, T."Chemotherapy continuity and incidence of febrile neutropenia with CHOP therapy in an outpatient setting". Molecular and Clinical Oncology 4.4 (2016): 591-596.
Chicago
Usami, E., Kimura, M., Iwai, M., Takenaka, S., Teramachi, H., Yoshimura, T."Chemotherapy continuity and incidence of febrile neutropenia with CHOP therapy in an outpatient setting". Molecular and Clinical Oncology 4, no. 4 (2016): 591-596. https://doi.org/10.3892/mco.2016.738